Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 85

recruiting
3 987
countries
28
conditions
2 109

1 221 trials match your criteria

Transitional cell carcinoma

Not recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Asthma

Not recruiting

Study on the Effectiveness and Safety of Budesonide and Formoterol Fumarate for Patients with Poorly Controlled Asthma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine

Neuroendocrine tumour+1

Not recruiting

Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Octreotide

Metastatic malignant melanoma

Not recruiting

Study on the Effects of EVX-01 and Pembrolizumab in Adults with Advanced Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:EVX-01

Systemic lupus erythematosus

Not recruiting

Study on Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine

Pulmonary arterial hypertension

Not recruiting

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib

Clear cell papillary renal cell carcinoma

Not recruiting

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Colitis ulcerative

Not recruiting

Study on Vedolizumab for Children with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Prednisone

Non-small cell lung cancer+2

Not recruiting

Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Lorlatinib

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Malignant melanoma+1

Not recruiting

Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ipilimumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.